Jaguar Announces Over-Enrollment In Its Pivotal Phase 3 OnTarget Trial Of Crofelemer For Prophylaxis Of Cancer Therapy-Related Diarrhea
Portfolio Pulse from Happy Mohamed
Jaguar Health has over-enrolled its global Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients by 11%, with 256 patients enrolled. Top line results from the study are expected in October 2023.
May 25, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health's over-enrollment in its Phase 3 OnTarget clinical trial of crofelemer for cancer therapy-related diarrhea may positively impact the company's stock in the short term.
The over-enrollment in the Phase 3 OnTarget clinical trial indicates strong interest and potential for crofelemer's success in addressing cancer therapy-related diarrhea. This may lead to positive investor sentiment and a short-term increase in Jaguar Health's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100